Disease Overview：Acute Lymphoblastic Leukemia（ALL）
Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy characterized by the uncontrolled proliferation of immature B- or T-lymphoid precursors in the bone marrow, peripheral blood, and extramedullary sites. It accounts for approximately 20% of adult leukemias and over 75% of pediatric cases. Diagnosis relies on morphologic assessment, flow cytometry immunophenotyping, cytogenetic analysis (e.g., detection of *BCR::ABL1*, *KMT2A* rearrangements), and molecular profiling to stratify risk and guide therapy. Standard treatment involves multi-phase chemotherapy—induction, consolidation, maintenance—and may incorporate targeted agents (e.g., blinatumomab, inotuzumab ozogamicin), tyrosine kinase inhibitors for Ph+ ALL, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in high-risk or relapsed/refractory disease. Five-year overall survival exceeds 90% in children but remains 40–60% in adults, underscoring the critical importance of timely, protocol-driven care at specialized centers.
China offers distinct advantages for ALL management: its leading oncology hospitals—such as Peking University People’s Hospital and Shanghai Ruijin Hospital—host nationally accredited leukemia centers with deep expertise in minimal residual disease (MRD)-guided therapy and complex allo-HSCT. Advanced infrastructure includes next-generation sequencing platforms, digital flow cytometry, and CAR-T manufacturing facilities approved by the NMPA. Clinical outcomes align with international benchmarks: published data show 5-year OS of 68% in adult standard-risk ALL and >85% in pediatric cohorts. Treatment costs are typically 40–60% lower than in the US or Western Europe without compromising quality—chemotherapy regimens, MRD monitoring, and first-line allo-HSCT are all available at transparent, all-inclusive pricing.
As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: coordinating referrals to JCI-accredited institutions, verifying physician credentials, arranging visa support and accommodation, and providing itemized cost breakdowns upfront—ensuring clarity, continuity, and clinical confidence throughout the care journey.
Acute Lymphoblastic Leukemia: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Acute Lymphoblastic Leukemia (ALL)
Non-Surgical/Medical Therapy (Standard Risk & High-Risk ALL)
*Eligibility*: Newly diagnosed, relapsed/refractory, or post-remission consolidation candidates; excludes active CNS involvement requiring intrathecal therapy.
- •Induction Chemotherapy (4–6 weeks)
- *Supportive Care*: Blood transfusions ($180/unit), G-CSF ($240/dose × 5 doses = $1,200), IV antibiotics ($360/course) - *Monitoring Labs*: CBC/differential ($12), peripheral smear ($8), bone marrow biopsy ($290), flow cytometry ($380), PCR for *BCR::ABL1* ($420) - Total Induction Tier: $2,815–$3,120
- •Consolidation/Intensification (12–16 weeks)
- *Lumbar puncture + intrathecal methotrexate* ($185/procedure × 4 = $740) - Total Consolidation Tier: $1,450–$1,780
- •Maintenance Therapy (2–3 years)
- Annual Maintenance Cost: $4,560
Procedural/Interventional Options
*Eligibility*: Refractory disease, minimal residual disease (MRD+) after 2 cycles, or relapse with salvageable status.
- •Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
- *Procedure & Hospitalization (30-day inpatient)*: Conditioning regimen ($2 cell infusion ($1,450), GVHD prophylaxis ($1,920), ICU support if needed ($3,600) - Total allo-HSCT Range: $10,525–$12,800
Therapy (for R/R B-ALL) - *Eligibility*: CD19+ relapsed/refractory ALL, adequate organ function - *Process*: Leukapheresis ($1,100), manufacturing ($14,200), lymphodepletion chemo ($1,850), inpatient monitoring (14 days, $4,200) - Total CAR-T Range: $21,350
Special/Complex Condition Management
- •CNS-Positive ALL: Intrathecal triple therapy (methotrexate/cytarabine/hydrocortisone) × 12 doses ($185/dose = $2,220) + cranial irradiation ($3,800)
- •Ph+ ALL: Dasatinib ($1,280/month) + chemotherapy; 12-month targeted therapy cost: $15,360
- •Pediatric Protocol (≤18 years): Reduced-intensity reg: $18,900 (vs. adult $28,500)
Quick Selection Guide
- •Children (<10 years, standard risk): Standard chemotherapy only — optimal; total 3-year cost: $18,900
- •Adults (18–60 years, MRD+ after induction): Proceed to allo-HSCT — curative intent; cost:60
- •Elderly (>60 years, comorbidities): Low-intensity chemo + targeted agents (e.g., blinatumomab $8,400/cycle); avoid transplant — cost-effective safety-first approach
- •R/R B-ALL (any age): CAR-T if CD19+, otherwise salvage chemo → allo-HSCT; $21,350 justifies survival benefit in fit patients
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Acute Lymphoblastic Leukemia Medical Vacation Packages
Curated transparent all-inclusive packages combining Acute Lymphoblastic Leukemia treatment with China top medical destinations:
